Parkinson's disease (PD) is a neurodegenerative disorder that primarily affects the dopaminergic neurons in the substantia nigra, leading to motor and non-motor symptoms. As healthcare professionals, understanding the complexities of PD is crucial in providing optimal patient care.
The etiology of PD is multifactorial, involving both genetic and environmental factors. Pathologically, PD is characterized by the accumulation of alpha-synuclein, forming Lewy bodies, and the loss of dopaminergic neurons in the substantia nigra. These changes lead to a decrease in dopamine levels, which is responsible for the motor symptoms observed in PD.
PD presents with both motor and non-motor symptoms. The cardinal motor symptoms are rest tremor, bradykinesia, rigidity, and postural instability. Non-motor symptoms include autonomic dysfunction, sleep disorders, cognitive impairment, and depression. These symptoms can significantly impact the quality of life of patients.
Diagnosis of PD is primarily clinical, based on the presence of the cardinal motor symptoms and response to dopaminergic therapy. Neuroimaging techniques and biomarkers can aid in the diagnosis, but they are not definitive. Early diagnosis and management are key to improving patient outcomes.
The mainstay of treatment for PD is pharmacological therapy aimed at increasing dopamine levels or mimicking its effects. Non-pharmacological interventions such as physiotherapy and occupational therapy also play a crucial role in managing the symptoms and improving quality of life.
PD is a complex neurodegenerative disorder with a multifactorial etiology and diverse clinical presentation. As healthcare professionals, our understanding and management of PD need to be comprehensive and patient-centered, focusing not only on the motor symptoms but also on the non-motor symptoms that significantly impact patients' quality of life.
1.
Can Concurrent Boost Safely Shorten Breast Cancer Radiation?
2.
Study shows supervised exercise improves strength, physical performance in patients with advanced breast cancer
3.
Ultrasound bras; HPV and thyroid cancer; language minimizing adverse events.
4.
In patients with advanced lung cancer, cemiplimab combined with chemotherapy extends life and enhances quality of life.
5.
The FDA Approves the New Frontline Aggressive ALL Regimen.
1.
Hematopoietic Stem Cell Exhaustion in Blood Disorders
2.
Lymphomatoid Papulosis: What You Need to Know
3.
The Growing Crisis of Aplastic Anemia: A Call for Action
4.
Importance of Early Detection in Hematology
5.
Clonal Hematopoiesis Dynamics and Future Hematologic Outcomes
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part X
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Further Discussion on A New Perspective
5.
Lung Cancer: Risk Factors and Prevention
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation